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Introiluctron
The so-called therapeutic range in oral anticoagulant treatment is the intensity of
h5rpocoagulability to be attained and maintained in patients in order to prevent the
occurrence or progression of thromboembolic disease. The h;ryocoagulability is
assessed by biological methods, i.e. coagulation time assay procedures; the range to
be aimed a is usually defined by a lower and an upper limit, expressed as percentages
of normal coagulabiJity.
The assay procedures currently used for the assessment of the therapeutic range are
all based on the original procedure first described by Quick in 1935 (1), which still
enjoys and excellent reputation as the so-called Quick one-stage prothrombin time
estimation, usually abbreviated to Quick test or prothrombin time. In this test, ox-
alated plasma is recalcified at 37' C after the addition of a suspension of acetone-dried
rabbit brain powder, called thromboplastin. However, the great majority of the
patients are no longer checked by Quick's original procedure, because many modifica-
tions include the use of capillary blood instead of venous blood and the substitution of
citrate for oxalate in decalcification. Of much greater impact have been the modifica-
tions in the preparation of thromboplastin and, even more important, the replacement
of rabbit brain thromboplastin by various tissue preparations deriving from other
species. The latter change was mad.e for economic as well as biological reasons. Human
brain material, for instance, was not only readily available in some countries, but also
appeared to excel over rabbit brain material in sensitivity to changes in coagulability.
Expression of Results as " Percentage ol Normality"
Results obtained with the coagulation time assay procedure are often expressed as a
"percentage of normal". Ilowever, it is not sufficiently known that the percentages
obtained. with the various methods differ widely in biological significance. Percentages
obtained with different methods are hardly ever comparable. One of the main reasons
for this divergence is that for the Quick method the percentages are calculated by
reference to coagulation times obtained with normal plasma diluted in saline, so that
the dilution of Factor V plays a role, whereas for Thrombotest as well as the P & P
method the reference culves are obtained with normal plasma diluted in a milieu in
which only the vitamin K-dependent factors are rate limiting. However, with both
procedr:res introduced by Owren (the P & P method and Thrombotest) the results
found in patients are also mutually divergent, the Thrombotest "percentages" being
Thrombos. Diathes. haemorrh. (Stuttg.)
570
about one half those found with the P & P method. The reason for this divergence is
that Thrombotest is particularly sensitive for PIVKA, a pro_tefn anticoagulant
*** 
in the circulition aur6g coumarin treatment (PIVKA being the abbrevia-
tio" of pilteln Ind.uced by Vitamin K Absence or Antagonislt {+tt' ..
IJnawareness of the wihe divergence in the significance of t'hese- "percentages" has
leJto ambiguities an4 hence to 
"d*.g"roo* 
conlusion with regard to optimal thera-
peutic levehl This situation explains ira'y{ailures in anticoagula-nt treatment during
the past twenty years, and *#"* standaidization imp,erative. These difficulties mav
be iliustrated by Lxperience in The Leiden Thrombosis Service'
In the Leiden ,I,hrombosis Service over more than 30,000 patient years of coumarin
treatment, it has been shown that the ease with which adequat'e anticoagulant therapy
is maintained clepend.s, in ad.dition to tight supervision of the patient and' the choice of
the anticoagulaft, to a great, extent oith. t.lh.bility ol the method used to evaluate
coagutationl At the Leid"en Thrombosis Service, three different methods and thrombo-
otr&i,' preperations have been tried during the past fifteen years: .in the beginning,
6;i;;t"#-i"g" pr"tn".mbin time assayprocedrire with human brain thromboplastin
was used; later, because of a shortag" oi io*utt brain material, a commercial rabbit
Iung thromboplastin preparation ino"1") was applied,-and finally' since 1963'
Thr"ombotest 1foyegra"A; lias been used.. Thrombot"Jt -u. chosen upon the recommen-
dation of the scientific committee for the Thrombosis services of the Dutch Red
Cross, which considered Thrombotest to offer the most reliable results, particularly
because it provides a reproducible value for normal plasma (16)' 
.
The search for the sol-called, therapeutic range, i.e. ttie range between the limits of
*fri"f, nypo"oagulability induced bf coumariri congeneTs should be maintained, has,
for any given assay piocedure, been a matter of lrial and error. Tn the extensive
material of the Leiden Thrombosis Service, a therapeutic range _of 15 to 30 "per.cent"
according to Quick has proven to be adequate wheiuse was maile of human brain and
Roche thromboplastinl Wittr the intro-d.uction of Thrombotest aft'er an extensive
"o*parativ" 
*toay 1fOl, a range of 5 to 10 "per cent" was adopted instead' of the
recommend.ed 10 to 21""per 
""it". 
Fot .u*u* of- active venous thrombosis, even lower
values (4to 8 "per ."ni';i""r" rimed at, and_in_patients with relative contra-indicat'ions'
values lower than 7 "per cent" were avoided.-as much as pogsib_I9 It is interesting to
note that poller, who iov"rs a population of 15 million with his Manchester Compara-
lir." n"rg"rrt (a human brain niatierial), proposes a therapeutic ralgq of 15 to 30 ..p-:r
cent,,,, a i,nge'he showecl as early as 1062 to equal 5 to 1.0-';per cent" Thrombotest (17)'
f .ffo-irg tfrese guidelin"*, -" hi,-r" obtained highly satisfactory prophylaxis of venous,
intracardial, and arterial ihrombosis as well u. t".t"i"tion to an acceptable -number of
bleeding complication. 1ts, to, 20). similar experience has been reported bv" 91h:t
investig-ators\Zt,ZZ1.;11o*"rr"r, tor ttre P & P-methocl, a therapeutic range of 10 to
i5 "p.i 
""n1"'was 
originally proposed (2), but' 10 to 20 "pet cent" may even be more
, ua"qout. (23). Un{ort"unatety, nianufacturers of thromboplastin preparations 1".9T-
mend therap"oti. ,ung;; tiat may result 
_in insufficient anticoagulation {24)' The
reverse - institution of- 
""""*.ir." 
anticoagulation - may also be the case when using
the therapeutic ranges recommended by manufact'urers (25'26)'
From the foregoing lt i. .l"ur that 
:'percentages" found with one thrombonlagtin
pr"pu"u,tion cann-ot b? equate{ with the^percentige_ found, with another. These differ-
irr. i. *r" explained by what is known about-the mode of act,ion of coumarin eongeners,
the assay pr'o""dor"*iu"J tfr" interaction of coagulation factors.Itor these reasons the
percentage activity a"-ri-rJ t"o^ (saline) dilutlon curves is indicated by the use of
inverted commas in tbis communication'
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The Sensi,tiuity ol Thromboplasti,n Preparations to the Delect Caused' by Coumari,n Drugs
The sensitivity of a thromboplastin preparation may be assessed by the extent of
prolongation of Llotting time in a test sample compared t'o normal. Since the various
inethods have different normal clotting times this sensitivity may be recorded using the
clotting time ratio (the clotting time of the test sample divided by the clotting time
of the normal sample).
If the "therap".iti" rutrg"" adopted by the Leiden Thrombosis Service is used for
purposes of comparing different preparations, it is found that the most sensitive assay
iro-cedure is that introduced by Owren in 1951, the so-called P & P method (2). For
th" ,urrg" ad.opted as optimal by the Leid.en Thrombosis Service, the difference in
these ral,ios *ith thl. procedure is approximately 3.3 (e.g. a range of 3.7-7). Quick's
assay procedure withlhe use of human brain thromboplastin displays a distinctly
lower Jensitivity, from 1.0 to 1.5 (".g.a range of 2.3-3.4), dependent on the mode of
preparation of the thromboplastin. For commercially available th-roTboplastin pre-
i""-rtion* the sensitivity is stitl lower, rabbit brain preparations displaying a differ-
6nce in ratios as small as 0.50 (a range of 1.5-2.0). Thrombotest, a reagent introduced
by Owren in 1959 (3) contains bovine brain thromboplastin and an excess amount of
fitrinogen and factor V, by which specifically the vitamin K-dependent coagulation
factorJbecome rate Limiting in the coagulation reaction. This reagent is unequivocally
more sensitive than any other commercially available thromboplastin preparation, th9
difference between the prolongation ratios limiting the therapeutic range being 1.6
(a range of 2 .5-4.I).
Stond'ard"izat'ion
From this discussion the need for a reliable standardization procedure by which the
results of one centre may be correlated with those of another is obvious. In 1963,
Miale proposed the use, in addition to meticulously standardized assay techniques, of
standJrcl 
-plu.-u* 
containing a normal amount of factor V and fibrinogen and krrown
amounts 6f factors II, VII, and X at different levels (5); coagulation times found with
these plasmas could then be used as monitors of normality and of the limits of the
therapieutic range. Commercially prepared standards have already been used in daily
qualiiy control{0, Z;. Sigg* utrd D"nson (1967) approached the_problem from a diffe-
rent angle. Using the clotting time-ratio for comparison they found that the results
with one thromboplastin were well correlated with those using another when a num-
ber of samples froin patients receiving coumarin drugs were tested (8). They thought
that a norinal reference plasma would not be needed. Loeliger and co-workers used
pooled normal and pooled coumarin plasma stored at -70o C, which permit st^an-
hardization in "absolute" terms, i.e. in terms of the activity of two coagulation fac-
tors, the factors II and. X, circulating in the patient's blood (9). This last approach has
been extended, giving the results reported in this paper. The results reported here also
suggest that the mosiprofitable approach may result frgm a combination of the meth-
oa.1t Miale (1g63 Plasma Standards) and Biggs and Denson (1967 Thromboplastin
Standards).
Material and Methoils
Plasmu
Normal plasma
Normal plasma consisted of a pool of equal parts of platelet-poor plasma prepared from 30 healthy
individuals with an average of approximately 30 years and a sex ratio of 1:1. The material was
stored at - 70" C in small portions for daily use (batch 1502). Batch 1504 was prepared similarly,
but was stored at -25" C.
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Plasma Lo be tested
plasma to be tested rffas ;btained from patients.and. one volunteer displaying stable anti-
coagulation. The pafients had been treatecl for coronary or peripheral atherothrombosis on'a long-
terrn basis und.er the supervision of the Thrombosis Service of Leiden' Individual plasmas were
tested withou,t delay, wheroas pooled plasma and plasma from the voluntoer were chocked only
after storage for 1-4 months at - 70o c. seven pools were prepared, each of them from 30 patient's;
to obtain pools with mutually differing levels of hylocoagulability, the patients were carefully
selected according to intensity of anticoagulation. It proved difficult to collect on one day from'
30 patients d.isplaying insufficient anticoagulation the material required for a pool with a relatively
higi activity o1 coagulation factors. Most of the patients whose plasma was included in the pools
had been treated.with the long-acting coumarin preparation phenprocoumon, but several of the
patients whose plasma was investigated individually had been treated with the short-acting
coumarin preparation acenocoumarin.
P r eqt ar a li,on oJ pld snla
fn Uotf, p"tllrrt" and normals, venapuncture was performed with a disposable needle and blood
was collected, without the use of a sy'ainge, directly in plastic tubes containing 0.55 M sodium
citrate, so as to obtain a final conce.ntration of 0.011M sodium citrate, Blood for immediate
investigaf,ion was centrifuged once at room temperature for 10 min at 3,000 rpm' For plasma to be
stored at - 20. C, a seconJcentrifugation, at 4o C for 30 rnin at 20,000 g, was applied. The duration
of the interval betwoen venapuncture and storage of the plasma at -70" c amounted to up t'o 8 hrs
(patient pools); plasma was kept at, room temperatule for not more than 8 hrs. Except for the
.,l.rrrp,,,.ito". ne-edle, blood and plasma were handled with plastic or siliconized materials'
Ly ophi,Li,ze d's Land'rtrd" plasma
"D-iagnostic plasma (batch 04?90?8), verify I (batch 0906128), and verify II (batch 0907128), all
3 plasmas produced by Warner & Chilcott, Morris Plains, New Jersey, IISA'
standard I, II, and III: obtained through the courtesy of Dr. J.B.Miale, university of Miarni,
Coral Gables, X'lorida.
Al( O H ) ; adsorbed' plasma
1.0 rril normal pooled plasma was adsorbed with 0'1 nI 20o/o Af(OH)3 suspension for 3 min at
37. C. To get rid of the Al(oH)r, the plasma was careJul'l'y centrifuged three tirnes, first for 10 min
at 3,000 g and then twice for 20 min each at 20,000 g'
P r othr ombi,n - def'ci'ent pl'asrna
Prepared according to Koller et al. (10). In a sterile bloodbank bottle containing 1 ml human
brain ihromboplastin diluted 1:100 with barbital buffer, and ullder continuous shaking of the
bottle. 500 ml blood fro{n an arbitrarily-chosen donor is collected and allowed to coagulate for
24:hrs] at 37o C. The bottle is then centrifuged for 60 min (750 9), a,fter which the supernatant serum
is pipetted off, centrifuged for 30 min (750 g), and mixed with a 0.1 M sodium oxalate solution in a
ratio of 5: 1. The oxalated senrln is held for 48 hrs at 4' C and then mixed in a ratio of 1: 1 with
freshly prepared oxalated bovine plasma deficient in prothrombin and fact'ors vII, IX' and X,
through adlsorption onto BaSOn 100 mgiml. The mixture, which generally has a prothrombin
conteit of < lo/o,is stored in 1 ml aliquots in rubber-stoppored glass test-tubes at 
- 25o C'
ThromboPlasti'n
5 differenl, thromboplastin preparations were used:
L.Humam bra,in tlwombo,tlistin prepared according to Owren and Aas (11)' batch No'1910'
2. S4mplasti,n, batch No.b902128; produced by Warner & Chilcott, Morris Plains, New Jersoy,
U S A. (Dutch repr. : N. V. Substantia, Mijdrecht)'
Z. Thrombolci,iase,Gei,gg' ,batch No. 52/4 647 lllschweiz; produced by Geigy Ltd.' Basel, Switzer-
land (Dutch repr.: Propharma, Haarlem). 
Lud., Basel, Switzer_4. Thromboflast'in Ldsung 'Roche' , bat'ch No' B 60 1079, produced by R'oche
land (Dutch repr.: La Roche N.Y., Mijdrecht)'
S .Th rombo tes t , ba t chNo . l 23 ,p roducedbyNyegaa rd ,Os lo ,No rway (Du tch rep r ; :Pha rma-
chemie, Ilaarlem).
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Calc'ium Chlorid,e
Solution of l/uo M, except for Thrombotest, for which a 3.2 mM solution is used.
Buffer
Barbital sodium acetate buffer (pII 7.4), according to Micha6lis.
Test Tubes
Blood and plasma were stored in polystyrol crystal tubes with polythene cap. Determinat'ions
of clotting times were performed in disposable glass test-tubes (10-11 x 55 ml) held at 37' C in a
waterbath.
T hromboTtlasti,n T i,me Assay Procedure
The thromboplastin time assay procedure was meticulously standardized and performed
according to Quick's and the manufact'urer's directions. Patient and normal plasmas were tested
in parallel t'o exclude t'ime influences as much as possible. All determinations were performed in
duplicate, except for those performed on normals tested in parallel with the pooled patient plasmas,
which were tested in quadruplicate. For the calculations, the mean of the 2 (or 4) values was used.
The coefficient of variations for Geigy thromboplastin, Simplastin, and Thrombotest times are
distinctly lower than those for human brain and R,oche thromboplastin: in skilled hands, this value
is about 3o/o for the first 2 of these preparations and 4-8lo for the other 3. For Geigy thrombo-
plastin, however, t'he normal value depends on the scrupulousness with which the suspension is
prepared. The normal value obtained with Roche thromboplastin depends to an important degree
on how t'he reading is done; values lying between 13.5 and 16.5 sec were obtained.
Ectctor II Assay Procedure
The activity of prothrombin was determined according to the one-stage principle. R,outinely,
0.1 ml artificially factor II deficient plasma, 0.1 ml diluted test plasma (normal or abnormal), and
0.1 mI human brain t'hromboplast'in are successively brought into a test tube at 37" C and thor-
oughly mixed. Recalcification is performed without delay with 0.1 CaCl, r/.0 M. The plasma-
thromboplastin-calcium mixture is vigorously mixed in an automatic mixer. Abnormal plasma is
diluted 1:10 and 1:20, whereas the normal reference plasma (here batch 1504) is diluted 1:20,
1:40, 1:80' and 1: 160. The deiermination of normal and abnormal plasma is done in parallel, to
rule out changes of the act'ivity of thromboplastin with the duration of incubation. Results a,re read
from a straight line drawn on double log paper through the 4 points obtained from the values
obtained for the dilutions of normal plasma. The coefficient of variation of the resulting percentage
approximates 10o/o.
Fctctor X Assau Proced,ure
From normal pooled plasma and test plasma with a Thrombotest, time shorter than 100 sec,
dilutions with Michaelis buffer are prepared in siticonized or plastic test tubes (1:2, l:3, I : 4, and
1:5 for  undi lutedpat ient 'splasma and 1:3,  7:5,  l :7,  and 1:10for  normal  p lasma).  For samples
with Thrombotest times of more than 100 seco normal pooled plasma is added to the test plasma
1 : 10 before the dilutions are prepared. The reason for the addition of this normal plasma is to obtain
shorter coagulation times, since Thrombotesi times longer llnat 250 sec are difficult to read. The
plasmas and each of their 4 dilutions are t'ested in duplicate; 0.05 ml is added to 0.4 ml Thrombo-
t'est' reagent. The results are plotted on a t/D plot, and the best,-fitting straight line is drawn through
the points. The steepness of the curve obtained with the test plasma in relation to that obtained
with normal plasma gives the factor X activity in per cent as has been shown by Ilemker et al. (12).
From the percentage obtained for a test plasma to which normal plasma has been added, 10o/o
must be subtracted and the resulting percentage multiplied fry ]9. The coefficient of variation of
the result obtained approximates 10o/o. e
Factor V Assay Procedure
Done according to Borchgrevink (13).
Eactor VII Assay Proced,ure
This procedure is very similar to the factor II ass&y except, for the use of factor VII-poor plasma,
which was prepared according to Lechner and Deutsch (14).
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Results
Most of the results obtained from the comparqtive study of thromboplastin
p""p*"tio"* are shown itt fig*. la, lb, and 2' In tlese graphs' the clotting time ratios
/ patient's time \ dete"mined with different thromboplastin preparations' are plotted
\ normal time /
on the y-axis on normal scale; on the x-axis, the corresponding coagulation factor
u.tirritiJ, (mean of the factor Ii and. X-activity) are ptott6d on a 1/c-scale (where c is
ih" 
"orr""otration). 1'h" 
*r*pf"* tested were ? samples of plagm.a, pooled from d'ifferent
natients unde" treatmlni ai diff"rent levels of 
-anticoigulation (solid circles) and
5;;#H;;i;;;.h *r*pl"* of which 8 belonged to a volonteer studied oYer a
period of time.
WithThrombotest ,ast ra ight l inewasobta inedfor thenormalp la-smaS,ndi ts
dilutions, and the ,"*lt. obtiined with Thrombotost in patient's an4 the volunteer
also strongly suggest t".tilin"utity; this rectilinearity is particularlv obvious for the
results obtained. *itrt-i"Lf"a couilarin plasma .u-pl"*.-Th" 
"*o"' 
found' with the
;;t"; 4 thromboplastii preparations b6come flatter towards the right. The cuwe
**""rra. most shar-ply i,' tt" f1"t*peutic range for Geigy's preparation, which contains
larEe amounts of fa"lot VII-Iike- material (15). Huila'br-ain t'hromboplastin and
fi;ffi"--,#;u"pirJJ aisplay atmo.t stlaight lines in the therapeutic range, the
flattening becoming 
""iJl.ii 
Ult*""n 5 and, i}olo coagulation factof activity' Finally'
Humon broin thromboPtostin
1(100%)
10(10%)
Fig. 1a.
5(zov.l
d i
D l o
Fig. 1 a, and 1 b. A t/D plot showing the rolation between prolongation ratios obtained with various
thromboplastin preparations and the level of factors If and X. The solid line represents the correla-
tion line as estimated by eye for coumarin plasmas; the dotted line was obtained from normal
plasma (batch 1502) and its dilution in Al(OH)r-adsorbed normal plasma. Solid dots represent
results found with pooled coumarin plasma, open squares refer to randomly chosen.patients, and
crossed squares t'o one"volurtteer:hn::3J:#"liffi$:,#ili".H,rXl"t'* experimental anti-
for Simplastin, the deviation from rectilinearity becomes apparent only at very low
coagulation factor activities (2.5*50/), which are not encountered in patients under
therapeutic conditions. The correlation lines given for patients were fitted by eye.
Particularly when the results obtained from pooled patients plasma are considered,
it is obvious without statistical estimations that the patient lines run above the lines
found for normal plasma and its dilutions (open circles), the distance between them
increasing progressiyely w-ith decreasing coagulation factor activity. This is again
particularly obvious for Thrombotest, the 'patient line' of which certainly does not
pass through point 1 : 1 of the diagram. As shown in n'ig.2, the correlation lines in the
therapeutic range can for all practical purposes safely be considered as rectilinear.
If rre consider the lines resulting from the comparison of coagulation times c.q.
ratios obtained from normal plasma and its dilutions in Al(OH)r-absorbed plasma
(n'ig.z), rectilinearity is obvious only with respect to Thrombotest, which is appa-
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1 1 0(100%) (10%)
zv( s % ) 40(2,s%)
Fig.2. Synopsis of the correlation lines found experimentally; for each thromboplastin, both the
lines found for patients and those based on normal plasma and its dilutions in Al(orr)3-adsorbed
normal plasma obtained with diiutions of up to 2.5o/o arc presented. The vertical dotted and solid
lines aro the lirnits of the therapeutic range empirically taken at (25 to) 20-10 (to 8) 
o/s' The seg-
ments of the patient's lines in tne t0-20o/o range ar'e accentuated.'It' is clear that for all practical
purposes these parts of the lines may be considered rectilinear'
rently free of coagulation factors of the prothrombin complex. No statistical estima-
fion#re needed t6 show that the curves obtained for all other thromboplastins_are not'
rectilinear but flatten towards the right. x'or Geigy's preparation the main and rather
abrupt change takes place between L1": t and 1fc : S (tOO-ZO%),r'hereas at higher
ail"d;". the-shape oi the curves is similar to those obtained wit'h Roche and human
brain thromboplistin, displaying distinct flattening in the region >ll":10 (<10%)'
in" 
"u"fy 
chan-ge in the diieciion"of the curve belonging to Geigy's preparation is caus-
ed by thl high imounts of factor VII or factor VII-like activity present in this prepara-
ilorr"1O, f S;l the flattening of the rest, of the curve, as in the c'rves found with the
;tt;r'pt"#iations, indicaies contamination with factor VII and/or factor X activity'
such contamination is to be expected for human brain thromboplastin, 113e the
brains are not freed of blood remaiining in the intracerebral regions. Roche and warner
Ctritcott's preparations are probably Jso not completely free of coagulation factors'
The patienis, curves .."io to lustity two main conclusions: 1. the general pattern
follows'that of the lines obtained wiih normal plasma, and 2. a shift to the left in
comparison with normal plasma dilutions.is nbt to be denied, being -particularly
obvious for Thrombotest,Loman brain and, Roche thromboplastin, and very.prob-
able for Geigy,s preparation and Simplastin. The first conclusion suggests similarity
between nor"mal itui*u and patient's-plasma, whereas the second indicates the pres-
ence of an additi6nal factor. fndeed, pl-asma obtained. from patients under stable anti-
coagulation may be considered as diuted plasma as far as the activity of factors II,
VII. IX. and X is concerned; these 4 faciors, like the dilutions of normal plasma,
i
I
I
I
I
I
I
l
100
foctor
D l  t
displaying-similar activities (29, 30). Regarding the second conclusion, we would. like
to stress that, for Thrombotest, the patient's line, in all probability intercepts the
y-axis at the same point as does the normal line, a finding tb be expected in tlie pres-
ence of a competitive inhibitor, the amount of which is independent of the level of
anticoagulation, such as is the case for PI\IKA (4). Similar ieasoninq holds for the
results obtained wjth the other thromboplastin preparations, although-a much larger
series will be needed for statistical confirmation.
The scatter around the curves is distinctly smaller for the pooled coumarin plasma
samples than that for individual plasmas. This is due to the fact that (a) pool* *e"e
tested-by only one operator; but, more important, (b) inctiviilual plasmas show a
rather large variation in the activity of the factors depressed. by coumarin drugs; ex-
perience has shov'n that this variation amounts to about 20%n terms of the coef-
lcigt of variation (29, 30). The scatter is largest for human brain thromboplastin andRoche thromboplastin, due to the rather inconsistent normal values found with these
pleparations. The coagulation time end-point with Roche thromboplastin is less
clearly defined than that found with the otfer preparations, and human brain material
is slightly activated during incubation at 37' C.
Manufacturer's
proposal
Geigy's Thromboplastin
Ifuman Brain Thromboplastin
Roche Thromboplastin
Simplastin
Thrombotest
(16 )
(14)
(  13 )
(  15 )
(4.2)
20-34
16-30
16-30
18-35
5.4-LO.5
t5-25
15-30 (Poller)
t5-25
tI-25
to-20
Limits of the therapeutic range aceepted on the krasis of experienco at the Leiden Thrombosis
Service, expressed in percentages defined by the calculators furnished by the manufacturers of
thromboplaistin preparations. For human brain thromboplastin, a saline dilution curve obtained
from normal plasma has been taken as reference. The values in the righthand column refer to the
therapoutic ranges recornmended by the manufacturers,
The values given in Table 1 are derived from the data presented in X'igs. I and,2.If rt
is accepted that the coagulation factor activity (plotted on the x-axis)ls the ultimate
criterion for comparison, then the different thromboplastin preparations may be
assessed by determining the clotting time range with each thromboplastin which
correspo-nds to a particular range of factor activity. The therapeutic range adopted at
the Leiden Thrombosis Service corresponds to a factor activity range of (8:)10 to
20(-25) per cent. For the various thromboplastin preparations this absolute criterion
may be converted to "percentages" as determined by the manufacturers from dilution
curves. It will be seen once again that the "percentages" determined by the manufac-
turers bear little relation to the percentage coagulation factors. The therapeutic ranges
suggested by manufacturers (last column) also differ very markedly from the range
adopted by the Leiden Thrombosis Service with the exception of the Manchester
reagent and Roche thromboplastin.
Tabre 2 shows results obtained with 2 samples of lyophilized normal plasma (Dia-
gnostic plasma and Standard I) and 4 abnormal dried samples. It will be seen that
Table 1. Therapeutic Range in Currently llsed Terms.
Equivalent to levels of
(8) 10-20 (25) yo
coag. factor activity
Tablo 2. Coagulation Factor Activities (o/o).
Read from spocific assays
I I  l v  l v I I l x
Read from prolongation ratios
(Figs.  1f  2)
G  I H B I R  I S  I T T
Diagnostic plasma
Verify I
Yerify II
Standard I1)
Standard IIr)
Standard IIII)
95
22
10.5
1 1 0
t4
0
I U D
90
I D
70
60
45
1 5 0
oo
10.5
1 1 0
1 8 . 5
8
120
1 0
4.5
tl5
t 2
4.5
80
o
3.5
80
9.5
115
35
tJ. l)
80
t 7
7
1 1 5
23
b.,)
80
1 1 . 5
6
r20
23
o . D
90
l o
o
200
o  / . o
10 .5
r20
l 6 . D
o
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1) courtesy Dr. J.B.Miale, Miami, USA.
Coagulation factor activitios found in 'standard' plasmas, Warner Chilcott's Verify I and
II, and 3 experimental standards obtained through the courtesy of Dr. Miale. The activity of the
facf,ors of the prothrombin complex was assessed individually by means of specific one-stage assay
procedures (lefthand columns) and collectively (righthand columns) by transformation of the
prolongation ratios found with different thromboplastin preparations, using the correlation given
in Fig.2.
these samples differ markedly one from another in the relative amounts of factor II,
V, VII, and X tha,t they contain. It will be seen also that the various thromboplastin
prepara,tions assess these dried plasma samples differently depending on the parti-
culir sensitivity of the Thromboplastin. With factor X sensitiye preparations (such as
G"rgy'* thromboplqstin) the results approximate the factor X assay figures. O" llq
othei hand with Thrombotest, which is sensitive also to factorVII, the figures parallel
those for the factor V'II assay.
Table 3 gives the results of testing various batches of Thrombotest reagent with a
pool of normal plasma samples. The results show the great uri{ormity of this reagent
from one batch to another.
Table 3. Comparison of Thrombotest Batches.
Thrombotest
(batch no.)
Nyegaard
ro\yo I to"t,
Leiden.
L00o/o I  r0%
796
860
915
9 1 6
g t 7
9 1 8
919
937
mean
40
44
43
43
39
43
^ o
43
42.1
100
r t2
1 1 0
105
98
101
t04
106
104.5
4 l
44
44
4 1
39
44
/ q
n q
42 .1
99
tL5
1t5
oo
96
98
101
100
102.9
Compa,rison of values found with a series of different Thrombotest batches used to test, pooled
normal plasma (batch 1504) with the values takon from the reference curvo furnished by tho
manufacturer.
Discussion
With respect to the mode of action of coumarin congeners, three points may be
made on the basis of personal erperience (27). First, factors II, VII, IX, and X show a
I t  - -
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common pattern of response to an initial loading dose of anyone of several coumarin
congeners. This pattern is determined by the biological halftimes of the 4 coagulation
factors (28). Second, after the initial phase of unequal decrease. the 4 factors-- und.er
the influence of a constant maintenance dose - r"u.h u constant and mutually similar
level of lowered activity as assessed by one-stage assay techniques (2g, 30). Third, a
metabolic precursor of (one of the factors of the) prothrombin (complex) appears in the
circulatiori. This precursor, 'lvhich competitively inhibits prothrombin conversion and
the amount of rvhich is independent of the intensity of treatment, was initially called
preprothrombin (31) and later, less specifically, PrvKA (4). Recent investigations
have shown that at least part of this precursor may really be preprothrombin, sinc" rtt
appreciable and constant amount of slowly reacting prothrombin has been detected in
patients suffering from vitamin K deficiencv (32).
Concerning the assay proceduies used in the present study and the interaction of
coagulation factors, several important remarks must also be made. As to the stability
of coagulation factors: there is no meaurable cLifference between prothrombin times as
assessed with a series of different thromboplastin preparations beTore and after storage
at -70' C, particularly because factor V appears to be rather stable in platelet-free
citrated plasma stored at this temperature; activity of the vitamin K dependent
factors remains unaltered for years feven at -28 C (34)]. These observations show
that pooled samples from normal persons and patients stored aL -70o C may be used
for standardizal,ion.
Concerning the specificity of the assay procedures: the one-stage prothrombin time
test appears to be insensitive to rather large differences in the relative amount of pro-
thrombin (factor II) as deponstrated by a thorough study of carriers of severe ion-
genital prothrombin deficiency; all these carriers had normal prothrombin times in
spite of a 50o/o shortage of prothrombin (33). Nevertheless, prothrombin can be mea-
sured with great accuracy by a one-stage assay procedure (34). The fact that the result
is independent of the dilution shows that PIVKA has no inhibitory effect within the
test-system, and a falsely high activity due to PrVKA-thrombin is equally unlikely, as
may be concluded from the very low factor If activities found in cases of severe lonq-
lasting coumarin intoxications (34).
Factor VII, the second factor to be discussed in this context, can be safely monitor-
ed with human brain thromboplastin and rhrombotest (1b, 28); but Geigy's porcine
lung preparation, on the contrary, is highly insensitive to factor vrr.'fhe specific
assay procedures give highly satisfactory results (29, 30). However, because factor VII
is easily activated by contact and other not yet avoidable influences (35), we think
that it should not be considered as an equally reliable monitor in cases of stabilized
treatment.
With regard to factor X, studies on the reaction kinetics of the extrinsic coaEulation
system have disclosed that this factor is rate-limiting in the Thrombotest reaction.
This implies that Thrombotest can be used as a specific.factor X assay proced.ure i{
applied to a series of dilutions o{ the plasma to be tested (12). The accuracy of the
assay closely approaches that known for the prothrombin estimation, and is clearly
higher than the accuracy of the results found with the currently available one-stag-e
factor X assay procedures (34).
We may now return to the central difficulty in the use of the one-stage prothrombin
time, the problem of the large differences in the "percentages" currently used. rt has
been proven that the presence of PI\IKA is responsible for the fact that the "percent-
ages" obtained with Thrombotest are considerably lower than those obtained with less
sensitive or PlVKA-insensitive assay procedures such as the P & P method (4). On the
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other hanil, "percentages" calculated according to Quick are higher than would be
expected f*o-'the deprissed coagulation-factor levelin patients' plasmas' This differ-
en*ce is the result of the steepnesis of the standard. reference curve constructed on the
basis of Quick's original p"oi"clrrr" from the results obtained with saline dilutions of
normal piu**r; we"knori that d.ilution of factor V contributes considerably to the
relativefi. slow thrombin formation in saline d.ilutions. For such reasons the normal
plasma dilution curves cannot be used for standardization'
' 
Using the coagulation factor dilution curves (Figs. 1 and 2), it is found that in the
therapJrtic r,rng"., all curves may bc considered rectilinear (Fig.2). This means that
the results obtained. with differeni thromboplastins can easily be converted to a single
scale taking any one of the preparations talien as a reference thromboplast'in fmethod
of equival#t ratios of Biggs ,'n,1 D"n*on (8)1. We have already emphasised that the
therapeutic ranges indica't"ed by various manufacturers when assessed in terms of
coagrilation fact*or activity are very different (Tabie 2). In our opinion these diver-
g"ri"* may be durrg""orJ. For example, the Geigy recomm_endation of a range_of
itr-ZS,,p"i 
"ent" 
aclording to the Geily calculatoicorresponds-to 8-13o/o of coagula-
tion facior activity a levef which, in our opinion, should only be instituted in acute
thrombosis with nb contra-indications. Similarly, the recommended Simplastin rlnqe
of ll-25 "per cent" coresponds to a coagulation factor range of 6-140/0, wbich is in
our opinioi, a dangerons d"g*"" of anticoagulation for most patients' This last con-
clusio-n is in agreement with Ih" finding. of Rabiner (25), u'ho proposes that we aim at
a prolongatioir ratio of approximately f.Z, which corresponds to 25 "pet cent'" in
terms of Simplastin "percentages".
Another c6nclusion to be diawn from our results is that Thrombotest and human
brain thromboplastin display the highest sensitivity, 9"igy'l thromboplastin and
Simplastin the iowest. thiJ isimportarit, as the accuracy of results obtained, expressed
as pircentages, d.epencls not onl! on the experimental error in the reading of coagula-
tioir. times, 
"but 
also on the steepness of the correlation curve. The more sensitive a
thromboplastin preparation, thJ mor.e accurate the result. Thrombotest, e.g', which
displays'the ,uir" io* experimental error as Simplastin, surpasses its reliability
b"cro*" of a much higher'sensitivity. The most important' conclusion to be drawn
from our data, which ias alreaily been alluded to, is that the almost rectilinear corre-
lation between thromboplastin iime and coagulation factor concentration can be used
as a sound basis for statid,ard,i,zat'ion.Ir-fact,-Biggs and Denson based their standardi-
za,tionproposal on this correlation in 1967, altfiough they used a-reference thrombo-
piastin"rt'h"r than the coagulation factor activity as a standard (8) The conclusion of
biggs and Denson that a rJctilinear relationship exists between the ratios found with
trr"o"clifferent thromboplastin preparations in a series of randomly chosen coumarin
plasmas, has been prorr'"r statisticatty (36) and is consonant with our findings, at least
'u,s 
long as 'therap6utic' values are consideretl (9, 37). Not considered by Biggs and
Densoi, but equaily important for standardization, is the question of a constant nor-
mal comparison.
owren in 1959 introduced., together with Thrombotest (3) a painstakingly defined
standard reference curve which, as experience has shown (Table 3) gives a constant
normal value at 100 "per cent". However, the dilution curve does not reflect the true
coagulation defect induced by coumarin congeners, as explained, earlier.
Miale and La n'ond have suggested that in addition to meticulous standardization of
technique, carefully checkecl"p-lasma standards for monitoring normal and abnormal
Ievels should be usld as part bt th" du,lty quality control in the producers' and users'
laboratories (5). Their ap-proach, although still under investigation, has led to the pre-
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paration of commercially available diagnostic plasmas. Table 2 shows the results we
obtained in an investigation of bo-bh experimenial and commercially available plasma
standards. It appears that particularly two of the latter (Verify I and Verify II) iisptay
rather large mutual differences in the activity of the factors ir, vn, and k. fn" *.ti-
vity of factor VII is cle_arly higher than that of factor X. This explains the relatively
high percentages found when the over-all activity is tested *itL Th"o*botest and
human brain thromboplastin, both of which are t^o*., to be factor VII sensitive,
whereas the values found with Geigy's thromboplastin, which is factor VIf izsensitive,
closely parallel the factor X activiiy found in Verify I and II. Hence, these standard,s
hardly seem suitable for the standarclization of difierent thromboplastins. Moreover,
lhey lack PI\'IKA, so that in this respect too they do not reflect tffe true coagulationdefect induced by coumarin congeners. on the bther hancl, verify r and v"erify rr
lppear highly suitable for_the_ daily laboratory evaluation of similastin (6, T;. "Thedeep {rozen (- 70' C) samples derived from patients treated with coumarin drugs have
not shown these variations from one thromboplastin preparation to another Fig r).This is presumably because all were from patieirts treaied-with long-term anticoag:ula-
tion. rn these samples the concentrations of factors rr, v[, 
"ia 
x were eqially
reduced.
- 
In this paper we hope to have demonstrated that the preparation of referenceplasmas to be used for standardization of different u.**y pri"ilores monitoring the
coumarin-induced hJryocoagulability is feasible. As long as io internationally accJfted
qiT*l standard and/or reference thromboplastin(s) i"s (are) available, painstakiiigly
defined deepfrozen pooled normal and poolJd patients' plasma (the factor If and fac-
tor X activities of which are easily assessed) may faciliiate understanding. We hope
that the data on many aspects of the problem presented in this paper may assist in tle
ultimate choice of a method of standaidization which in our opiiiJn should involve the
use of a re{erence thromb-oplastin reagent and well clefined pia.-u samples from nor-
mal persons and from patients treated with coumarin 
"ons"r.:""..
Summary
_ 
The therapeutic range in oral anticoagulation, which is defined as the range ofh;4po_coagulability resulting. in optimal thrombosis prophylaxis and an acceplable
blee_ding tendency, is.monitoreil by_assay proceclu^res-of which the majorifr, are
modifications of Quick's original prothrombin time test. With respect to individualpatients on stabilized anticoagulation, the different modifications cdnmonly used give
the same information, the_ reliability depending more on the accuracy than on"the
sensitivity of the tests. The results do not appea" to be comparable in terms of
conventional reference curves or prolongatioo iatios of the coagirlation times found,but on the-basis of painstakingly definecl normal and patient"plasma, the mean of
the factor rr and factor X activity present in patients' flu,.*, p'"o-red to be a useful
common denominator. In terms of this co^motr denom-inator, tie therapeutic range
to be aimed at lies between (8 to)10 and 20(to 25)percent.
R6sum6
..Lazona th6rapeutique au cours de l'anticoagulation orale est c16finie par la zoned'h;,pocoagulabilit6 entre une protection optimale contre la thrombose et une tendance
aux h6morragie encore acceptable. Le contr6le est fait par des m6thodes de dosage engrande partie d6riv6es du temps de prothrombine d,ap-rds euick. En ce qui 
"orrJ"".r"
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l'anticoagulation stabilis6e, cinq modifications paraissent donner la m6me information.
La qualit6 d6pend davantage de l'exactitude que de la sensibilit6 des systdmes. Les
r6sultats ne sont pas comparables par usage simple des courbes de r6f6rence conven-
tionnelles ni par le calcul des rapports du temps de coagulation. Ils le sont seulement
sur la base de plasmas normaux et de malades trds soigneusement d6finis. La moyenne
d'activit6 des facteurs II et X s'est r6v6l6e 6tre un utile d6nominateur commun.
Calcul6e sur la base de ce d6nominateur commun) la zone th6rapeutique recommand6e
va de (8) 10 A 20 (25) pour cent.
Zusammenfassung
Das therapeutische Bereich der oralen Antikoagulantienbehandlung, welches als
jenes Bereich der Hypokoagulabilitrit definiert wird, welches zu optimaler Thrombose-
prophylaxe bei akzeptabler Blutungstend.enz fiihrt, wird durchBestimmungsmethoden
lestgestellt, welche in der Mehrzahl der n'd,lle auf Modifikationen der Original-Quick-
Methode zuriickgehen. Die verschiedenen gewohnlich verwendeten Methoden geben
bei individuellen Patienten mit, stabiler Gerinnungshemmung dieselbe In-formation,
deren Verls8lichkeit mehr von der Genauigkeit der Durchfiihrung als von der Emp-
findlichkeit der Teste abhei,ngt. Die Ergebnisse scheinen nicht aufgrund der iiblichen
Eichkurven oder aufgrund der Quotienten der Gerinnungszeiten vergleichbar zu sein,
sondern aufgrund des exakt definierten Normal- und Patientenplasmas, wobei das
Mittel der n'aktor II- und n'aktor X-Aktivitnt im Patientenplasma sich als geeigneter
gemeinsamer Parameter erwies. Aufgrund dieses gemeinsamen Pararneters liegt das
angestrebte therapeutische Bereich zwischen (B bis) 10 und 20 (bis 25) o/".
Atltlenilum
Since this paper was written, a series of results similar to those obtained in the
volunteer described here, have been obtainedin 12 patients on long-term anticoagu-
lant treatment, each of whom was tested longitudinally on 7 different occasions (half
of these patients were treated with the short-acting acenocoumarin, the other half
with the long-acting phenprocoumon). Preliminary analysis of the findings confirms
the tentative conclusion that the results obtained with the 3 different thromboplastins,
i. e. human brain, rabbit brain, and Thrombotest-thromboplastin, after transforma-
tion into ))our(( common denominator, do not differ significantly. ,
Discussion and. amendme.rt. i, 
"oop#Y::':f;K'". Biggs, Head of Research Laboratory,Oxford Haemophilia Centre, is gratefully acknowledged.
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